Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dalfampridine
Drug ID BADD_D00574
Description Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Indications and Usage Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS).
Marketing Status approved
ATC Code N07XX07
DrugBank ID DB06637
KEGG ID D04127
MeSH ID D015761
PubChem ID 1727
TTD Drug ID D08YIN
NDC Product Code 10144-427; 63190-0510; 67877-444; 56125-427; 0591-2533; 65862-917; 62756-429; 63629-9450; 65862-863; 38779-3205; 42571-338; 51927-5030; 42571-275; 0378-4504; 12817-054; 46016-5042; 54382-125; 62756-038; 62991-3143; 65372-1157; 16729-292; 63190-0530; 51407-246; 0054-0479
UNII BH3B64OKL9
Synonyms 4-Aminopyridine | 4 Aminopyridine | Dalfampridine | Pymadine | VMI-103 | VMI 103 | VMI103 | 4-Aminopyridine Sustained Release | 4 Aminopyridine Sustained Release | Sustained Release, 4-Aminopyridine | Fampridine-SR | Fampridine SR
Chemical Information
Molecular Formula C5H6N2
CAS Registry Number 504-24-5
SMILES C1=CN=CC=C1N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abnormal dreams19.02.03.001; 17.15.02.0010.004199%Not Available
Adenocarcinoma16.16.01.0040.000538%Not Available
Amnesia19.20.01.001; 17.03.02.0010.007483%
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001--Not Available
Anxiety19.06.02.002--
Aphasia19.21.01.001; 17.02.03.0010.003069%
Asthenia08.01.01.0010.075207%Not Available
Ataxia08.01.02.004; 17.02.02.0010.003930%
Atelectasis22.01.02.0010.000538%
Back disorder15.03.05.0030.002369%Not Available
Back pain15.03.04.0050.051951%
Basal cell carcinoma23.08.02.001; 16.03.02.0010.003015%Not Available
Bone disorder15.02.04.0040.000538%Not Available
Breast pain21.05.05.0030.001184%
Breast swelling21.05.05.0080.001830%Not Available
Burning sensation17.02.06.001; 08.01.09.0290.019111%Not Available
Calculus urinary20.04.03.0020.001454%Not Available
Carpal tunnel syndrome17.09.02.0010.002100%Not Available
Cerebral atrophy17.11.01.0010.000808%Not Available
Cervical dysplasia21.06.01.0020.001830%Not Available
Cervix carcinoma21.06.02.001; 16.12.01.0010.001184%Not Available
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.009--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Choking22.12.03.0030.002100%Not Available
Cholelithiasis09.03.01.0020.001346%Not Available
Chromaturia20.02.01.0020.006299%
Cold sweat23.02.03.002; 08.01.03.0240.002369%Not Available
Condition aggravated08.01.03.0040.072623%Not Available
Confusional state19.13.01.001; 17.02.03.005--
The 1th Page    1 2 3 4 5    Next   Last    Total 9 Pages